Highlights
– Amivantamab plus lazertinib produced an investigator-assessed objective response rate (ORR) of 52% in 105 patients with atypical EGFR‑mutant advanced NSCLC (median follow‑up 16.1 months).
– Responses were durable (median duration of response 14.1 months) and deeper and longer in treatment‑naïve patients (ORR 57%; mPFS 19.5 months; mDoR 20.7 months).
